Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/27014
Year of Publication: 
2007
Series/Report no.: 
Kiel Advanced Studies Working Papers No. 437
Publisher: 
Kiel Institute for the World Economy (IfW), Kiel
Abstract: 
We analyze the impact of national pharmaceutical regulation on the launch delay of new chemical entities approved by the EMEA's centralized procedure. We find that direct price control regimes have a significantly negative impact on the launch timing. These results cannot be found when investigating the impact of indirect price controls. Our results show that Germany (65%) has the highest probability of experiencing an early launch, while it is the lowest in southern European countries (18% for Portugal and 19% for Greece). This difference accrues from both price regulation and market attractiveness, since southern European countries generally have lower prices. Due to the possibilities for parallel trade within the EU, pharmaceutical companies, by acting strategically, may further increase launch delays.
Subjects: 
pharmaceuticals
regulation
new chemical entity
parallel trade
JEL: 
I11
I18
L51
Document Type: 
Working Paper

Files in This Item:
File
Size
207.42 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.